¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"fibroblast growth factors"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • growth inducer
    ¼ºÀåÀ¯¹ßÀÎÀÚ
  • growth line
    ¼ºÀå¼±
  • growth pattern
    ¼ºÀå¾ç½Ä
  • growth period
    ¼ºÀå±â°£
  • growth phase
    Áõ½Ä±â
  • growth plate
    ¼ºÀåÆÇ
  • growth quotient
    ¼ºÀåÁö¼ö, ¹ßÀ°Áö¼ö
  • growth rate
    ¼ºÀå·ü
  • growth rate constant
    Áõ½Ä·ü»ó¼ö
  • growth recovery line
    ¼ºÀåȸº¹¼±
  • growth regulator
    ¼ºÀåÁ¶ÀýÀÎÀÚ
  • growth retardation
    ¹ßÀ°Áö¿¬, ¼ºÀåÁö¿¬
  • growth spurt
    ¼ºÀå±ÞÁõ
  • growth zone
    ¼ºÀ屸¿ª, ¼ºÀå´ë
  • growth-onset diabetes
    ¹ßÀ°±â¹ßº´´ç´¢º´, Ãʱâ´ç´¢º´
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • macrophage-derived growth factor
    Å«Æ÷½Ä¼¼Æ÷À¯·¡¼ºÀåÀÎÀÚ
  • nerve growth factor
    ½Å°æ¼ºÀåÀÎÀÚ
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡¼ºÀåÀÎÀÚ, Ç÷¼ÒÆÇ±â¿ø¼ºÀåÀÎÀÚ
  • transforming growth factor
    Àüȯ¼ºÀåÀÎÀÚ
  • vascular endothelial growth factor
    Ç÷°ü³»ÇǼºÀåÀÎÀÚ
  • growth
    ¼ºÀå, Áõ½Ä
  • growth hormone
    ¼ºÀåÈ£¸£¸ó
  • growth inducer
    ¼ºÀåÀ¯¹ßÀÎÀÚ
  • growth line
    ¼ºÀå¼±
  • growth pattern
    ¼ºÀå¾ç½Ä
  • growth period
    ¼ºÀå±â°£
  • growth phase
    Áõ½Ä±â
  • growth plate
    (¢¡epiphyseal cartilage) »À³¡¿¬°ñ
  • growth quotient
    ¼ºÀåÁö¼ö, ¹ßÀ°Áö¼ö
  • growth rate
    ¼ºÀå·ü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • apical growth
    Á¤´Ü¼ºÀå, ÷´Ü¼ºÀå, ³¡¼ºÀå
  • appositional growth
    µ¡ºÙÀ̼ºÀå
  • grain growth
    ÀÔÀÚÀÇ ¼ºÀå.
  • growth
    ¼ºÀå, Áõ½Ä
  • growth abnormality
    ¹ßÀ°ÀÌ»ó.
  • growth abnormality
    ¼ºÀåÀÌ»ó
  • growth acceleration
    ¼ºÀå<Áõ½Ä>°¡¼ÓµµÇö»ó.
  • growth chart
    ¼ºÀ嵵ǥ(ËÛËöËÀ̰).
  • growth chart
    ¼ºÀ嵵ǥ(à÷íþÓñøú).
  • growth cone
    ¼ºÀå¿ø»Ô
  • growth constant
    ¼ºÀå»ó¼ö(¡­ßÈâ¦).
  • growth constant
    Áõ½Ä»ó¼ö
  • growth constant
    ¼ºÀå»ó¼ö(ÊÙË×Ëà).
  • growth curvature
    ¼ºÀå°î¼±(ÊÙË­ËÛ).
  • growth curvature
    ¼ºÀå°î¼±(¡­ÍØàÊ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cell growth pattern
    ¼¼Æ÷¼ºÀå¸ð¾ç<--¾ç½Ä>
  • cell growth,ligand receptor binding
    ¸®°£µå¼ö¿ë±â°áÇÕ (¡­áôé»ÐïÌ¿ùê)
  • curve, growth
    Áõ½Ä°î¼±
  • curve, single-step growth
    ÀÏȸÁõ½Ä°î¼±
  • cycle, growth
    Áõ½ÄÁÖ±â
  • developmental disease =growth abnor mal ity
    ¹ß´ÞÀÌ»ó(¡­ì¶ßÈ).
  • economic growth
    °æÁ¦¼ºÀå.
  • endothelial cell growth factor
    ³»ÇǼ¼Æ÷ Áõ½ÄÀÎÀÚ
  • epidermal growth factor
    Ç¥ÇǼºÀåÀÎÀÚ
  • epidermal growth factor
    Ç¥ÇǼºÀåÀÎÀÚ(øúù«à÷íþì×í­)
  • epidermal growth factor
    Ç¥ÇǼºÀå ÀÎÀÚ(¡­à÷íþ ì×í­)
  • epidermal growth factor (EGF)
    ÇǺÎÁõ½ÄÀÎÀÚ
  • epidermal growth factor = EGF
    Ç¥ÇÇ ¼ºÀå ÀÎÀÚ
  • epidermoid growth factor
    Ç¥ÇÇ¾ç ¼ºÀåÀÎÀÚ(¡­à÷íþì×í­)
  • essential growth factor
    ÇʼöÁõ½ÄÀÎÀÚ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • step-growth polymer
    ´Ü°è¼ºÀå ÁßÇÕü(Ó«Í­à÷íþñìùêô÷)
  • synchronous growth
    µ¿±â¼ºÀå (ÔÒÑ¢à÷íþ)
  • tail growth
    ²¿¸®¼ºÀå (à÷íþ)
  • tailward growth
    ²¿¸®¹æÇâ ¼ºÀå (à÷íþ)
  • T cell growth factor
    T ¼¼Æ÷¼ºÀåÀÎÀÚ (á¬øàà÷íþì×í­)
  • transforming growth factor
    º¯Çü ¼ºÀå ÀÎÀÚ(ܨû¡à÷íþ ì×í­)
  • unbalanced growth
    ºÒ±ÕÇü(ÝÕгû¬) ¼ºÀå (à÷íþ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
FGFA fibroblast growth factor, acidic
FGFB fibroblast growth factor, basic
FGFR fibroblast growth factor receptor
ANF Atrial Natriuretic Factors
ECF   1) Eosinophilic Chemotatic Factors
  2) Extra-Cellular Fluid; ¼¼Æ÷ ¿Ü¾×
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
basic FGF Basic fibroblast growth factor
FGF C--fibroblast growth factor
FGF-1 Fibroblast Growth Factor
FGF-2 Fibroblast Growth Factor
FGF10 Fibroblast Growth Factor 10
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • too much growth
    Áõ½Ä
  • total growth
    ÃÑ Áõ½Ä·®
  • tumor growth
    Á¾¾ç ¼ºÀå
  • uncontrolled destructive growth
    ºñÁ¶Àý¼º ÆÄ±«¼º ¼ºÀå
    ÀÎÀ§ÀûÀ¸·Î Á¶ÀÛÀÌ ¾ÈµÇ°í ÀÚ¶ó¸é¼­ ÆÄ±«Àû ¼ºÁúÀ» Áö´Ï´Â °Í.
  • vascular endothelial growth factor
    ¸Æ°ü ³»ÇǼ¼Æ÷ ¼ºÀå ÀÎÀÚ, Ç÷°ü ³»ÇǼ¼Æ÷ ¼ºÀå ÀÎÀÚ
  • vertical growth
    ¼öÁ÷ ¼ºÀå
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
C factors Proteins that restore phosphorylating ability to mitochondria that have lost it, i.e., have become "uncoupled" so that oxidation and electron transport no longer produces ATP. Usually termed coupling factor F1, F2, etc.
Synonym: C factors.
(05 Mar 2000)
r factors A class of plasmids that transfer antibiotic resistance from one bacterium to another by conjugation.
(12 Dec 1998)
rheumatoid factors Antibodies in the serum of individuals with rheumatoid arthritis that react with antigenic determinants or immunoglobulins that enhance agglutination of suspended particles coated with pooled human gamma-globulin. Rheumatoid factors also occur in other autoimmune and certain infectious diseases.
(05 Mar 2000)
chemotactic factors Chemical substances that attract or repel cells or organisms. The concept denotes especially those factors released as a result of tissue injury, invasion, or immunologic activity, that attract leukocytes, macrophages, or other cells to the site of infection or insult.
(12 Dec 1998)
chemotactic factors, eosinophil Cytotaxins liberated from normal or invading cells that specifically attract eosinophils; they may be complement fragments, lymphokines, neutrophil products, histamine or other; the best known is the tetrapeptide ecf-a, released mainly by mast cells.
(12 Dec 1998)
chemotactic factors, macrophage Cytotaxins liberated from normal or invading cells that specifically attract macrophages. They may be lymphokines, products of antigen, antibody and complement interactions or other.
(12 Dec 1998)
risk factors An aspect of personal behaviour or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
(12 Dec 1998)
meteorological factors The atmospheric phenomena which pertain to climate and weather.
(12 Dec 1998)
clearing factors Lipoprotein lipases that appear in plasma during lipaemia and catalyze hydrolysis of triglycerides only when the latter are bound to protein and when an acceptor (e.g., serum albumin) is present, thus "clearing" the plasma.
(05 Mar 2000)
colicin factors Plasmids determining the potentiality of a bacterium to produce colicins. They are cytoplasmic elements whose integration into the bacterial chromosome has not been demonstrated except for the col b and col v factors.
(12 Dec 1998)
colonisation factors <microbiology> The pili on enteropathogenic forms of E. Coli facilitate adhesion of the bacteria to receptors (probably GM1 gangliosides) on gut epithelial cells and are often referred to as colonisation or adherence factors.
Colonisation factor antigens may be plasmid coded, are essential for pathogenicity and are strain specific, for example K88 diarrhoea in piglets), CFAI and CFAII on strains causing similar disease in man.
(18 Nov 1997)
cord factors Trehalose-6,6'-dimycolate. A toxic glycolipid of mycobacterium tuberculosis. Induces cellular biochemical disfunction in animals; used as immunoadjuvant.
(12 Dec 1998)
myogenic regulatory factors A family of muscle-specific transcription factors which bind to DNA in control regions and thus regulate myogenesis. All members of this family contain a conserved helix-loop-helix motif which is homologous to the myc family proteins. These factors are only found in skeletal muscle. Members include the myod protein (myod protein), myogenin, myf-5, and myf-6 (also called mrf4 or herculin).
(12 Dec 1998)
coupling factors Proteins that restore phosphorylating ability to mitochondria that have lost it, i.e., have become "uncoupled" so that oxidation and electron transport no longer produces ATP. Usually termed coupling factor F1, F2, etc.
Synonym: C factors.
(05 Mar 2000)
haemolysin factors Plasmids controlling the synthesis of haemolysin by bacteria.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á